Cannabinoids for Psoriasis: How Plant Compounds Might Calm an Overactive Skin Immune System

Narrative review of published literature on phytocannabinoid effects relevant to psoriasis pathophysiology. Covered mechanisms including modulation of oxidative stress, cytokine production, keratinocyte proliferation, and immune cell function. Examined CBD, THC, CBG, CBN, and other phytocannabinoids. Reviewed relevant receptor systems (CB1, CB2, TRPV, PPAR) in skin tissue.

Current psoriasis treatments include topical steroids (which thin the skin over time), immunosuppressants (which increase infection risk), and biologics (which are expensive and require injections). Many patients find these treatments inadequate or have significant side effects. If cannabinoid-based topicals could provide effective symptom relief with fewer side effects, they could fill an important gap — especially for mild-to-moderate psoriasis where current options are limited.

This review connects the skin-focused cannabinoid research to the broader anti-inflammatory evidence reviewed in RTHC-00098 (CBD and innate immunity) and RTHC-00097 (CBG in rheumatoid arthritis). The endocannabinoid system is present throughout the body, and inflammation is a common thread — what changes is the target tissue. The same CBD mechanisms that show promise for gut inflammation (RTHC-00108) and joint inflammation may be relevant for skin conditions.

Narrative review relying primarily on preclinical evidence. Almost no clinical trial data in human psoriasis patients. Laboratory findings in isolated cells and animal models often don't translate to effective treatments in humans. The skin is a complex organ with multiple cell types and immune dynamics that in vitro studies don't capture. Topical cannabinoid formulations face penetration and delivery challenges that laboratory studies bypass.